News / Taiwan / cnyes
Alvogen's Subsidiary Lotus Reports 81% Surge in August Revenue
Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-10
1795
Lotus Pharmaceutical reported August 2026 revenue of NT$2.11 billion, an 81.68% YoY increase, with cumulative year-to-date growth reaching nearly 70%.
What Happened
Revenue Surge: Lotus Pharmaceutical posted strong results for August 2026, with monthly revenue reaching NT$2.11 billion, representing a significant 81.68% year-over-year increase. Despite a slight month-over-month dip, the overall growth trajectory remains robust.
Cumulative Performance: For the first eight months of 2026, the company's cumulative revenue reached NT$22.05 billion, a year-to-date increase of 69.19%. This strong performance underscores the company's growing competitiveness in the pharmaceutical market.
Stock Performance: Shares of Lotus are currently trading at NT$177. The stock has seen a 2.48% decline over the past five trading days, underperforming the broader biotechnology index as the market remains relatively cautious.
Business Scope: Lotus operates within the biotechnology and healthcare sector, focusing on pharmaceutical manufacturing and retail. The company continues to leverage its diverse product portfolio to maintain a strong position in the pharmaceutical supply chain.